TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3901422

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30783259

Group type: EXPERIMENTAL
Intervention: Fluoxetine (oral) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29931076

Group type: EXPERIMENTAL
Intervention: Motolimod
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 27058159

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 188

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 188
Study: 24556428

Group type: EXPERIMENTAL
Intervention: Single-serving packages (SSPs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard packages (STPs)
Number of subjects: 64
Study: 22694905

Group type: EXPERIMENTAL
Intervention: Exposure therapy plus D-cycloserine (DCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure therapy plus placebo
Number of subjects: 0
Study: 20643006

Group type: EXPERIMENTAL
Intervention: Open functional neck dissection technique on the primary tumour side
Number of subjects: 25

Group type: COMPARATOR
Intervention: Functional neck dissection on the other side (control group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Open functional neck dissection technique
Number of subjects: 25

Group type: COMPARATOR
Intervention: Functional neck dissection (control group)
Number of subjects: 25
Study: 18648963

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 6 weeks)
Number of subjects: 21
Study: 11369675

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Old control subjects
Number of subjects: 45

Group type: COMPARATOR
Intervention: Young control subjects
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 9432038

Group type: EXPERIMENTAL
Intervention: BB-10010 (10 microg/kg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: BB-10010 (100 microg/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No BB-10010 (Control)
Number of subjects: 52
Study: 8517172

Group type: EXPERIMENTAL
Intervention: 5‐HT reuptake inhibitors
Number of subjects: 219

Group type: COMPARATOR
Intervention: Clomipramine (tricyclic antidepressant)
Number of subjects: 219
Study: 2948737

Group type: EXPERIMENTAL
Intervention: Methoxamine infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thymoxamine infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study: 29698416

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n = 38)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (n = 34)
Number of subjects: 72
Study: 27549382

Group type: EXPERIMENTAL
Intervention: Physical Activity 4 Everyone (PA4E1) intervention
Number of subjects: 837

Group type: COMPARATOR
Intervention: Usual physical activity practices (Control)
Number of subjects: 837
Study: 26009023

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Motivational computer program (MC)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Supervision as usual (SAU)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All groups (MI, MC, SAU)
Number of subjects: 600
Study: 23653149

Group type: EXPERIMENTAL
Intervention: 12 MHC class I‐restricted melanoma peptides (12 MP)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 12 MHC class I‐restricted melanoma peptides plus a tetanus peptide (group B)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 6 melanoma helper peptides (6 MHP) to stimulate helper T lymphocytes (HTL) (group C)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 6 melanoma helper peptide (6 MHP) alone (group D)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Immune response to 6 MHP
Number of subjects: 175
Study: 20691795

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 416

Group type: COMPARATOR
Intervention: Disease-modifying anti-rheumatic drug treatment
Number of subjects: 416
Study: 18647806

Group type: EXPERIMENTAL
Intervention: 40 mg pegvisomant (PEG‐V)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16671434

Group type: EXPERIMENTAL
Intervention: High SjO2 (SjO2 > 75%, H-group; n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal SjO2 (SjO2 <= 75%, N-group; n = 9)
Number of subjects: 19
Study: 12795573

Group type: EXPERIMENTAL
Intervention: Expectancy challenge intervention
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 216
Study: 10894309

Group type: EXPERIMENTAL
Intervention: Fee-for-service (FFS)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Health Maintenance Organizations (HMOs)
Number of subjects: 429
Study: 8676825

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (VLPD) with ketoacids (KA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Very-low-protein diet (VLPD) with essential amino acids (EAA)
Number of subjects: 8
Study: 1473292

Group type: EXPERIMENTAL
Intervention: 4 weeks of moderate exercise training
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 weeks of detraining
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (sedentary phase)
Number of subjects: 10
Study: 31961448

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model averaging via reversible jump markov chain monte carlo (MCMC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thresholds of TNE identified from compliant groups at each dose level
Number of subjects: 0
Study: 30488542

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29430253

Group type: EXPERIMENTAL
Intervention: High-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Middle-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low-dose Shen Guo Lao Nian Granule (SGLNG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 240
Study: 25678361

Group type: EXPERIMENTAL
Intervention: Chronomodulated chronoFLO4
Number of subjects: 361

Group type: COMPARATOR
Intervention: Conventional FOLFOX2
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Time-dependent covariate (TDC) analysis
Number of subjects: 361
Study: 23988786

Group type: EXPERIMENTAL
Intervention: 2.3 mg kg(‐1) body mass of pseudoephedrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.8 mg kg(‐1) body mass of pseudoephedrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21923964

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Number of subjects: 90
Study: 19473813

Group type: EXPERIMENTAL
Intervention: Newspaper article about the study
Number of subjects: 7233

Group type: EXPERIMENTAL
Intervention: More favorably written newspaper article
Number of subjects: 7233

Group type: COMPARATOR
Intervention: No newspaper article
Number of subjects: 7233

Group type: COMPARATOR
Intervention: Original newspaper article
Number of subjects: 7233
Study: 18767578

Group type: EXPERIMENTAL
Intervention: Moxibustion at Shenque (CV 8) combined with local electroacupuncture at Dubi (ST 35), Neixiyan (EX‐LE 5), Yanglingquan (GB 34) and Ashi points.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham moxibustion at Shenque (CV 8) combined with local electroacupuncture at the same points.
Number of subjects: 60
Study: 15943593

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study: 12680748

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10493678

Group type: EXPERIMENTAL
Intervention: 19 kDa protein of Yersinia enterocolitica O:3
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Anti-19 kDa IgG antibodies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Anti-19 kDa IgA antibodies
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: IgG antibodies to Yersinia outer membrane protein (YOP)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: IgA antibodies to YOP
Number of subjects: 76
Study: 8762385

Group type: EXPERIMENTAL
Intervention: Hand searching by both authors
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Independent assessment of topics of the reports
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Hand searching of the journal
Number of subjects: 105
Study: 1912887

Group type: EXPERIMENTAL
Intervention: Amoxycillin 125 mg three times a day for seven days
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 6348658

Group type: EXPERIMENTAL
Intervention: Tinidazole IV (1.60 g in 24 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ornidazole IV (4 g in 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31504952

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Enhanced probabilistic neural network model
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Neural dynamic classification algorithm
Number of subjects: 47
Study: 28708126

Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26068295

Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 4 years
Number of subjects: 4074

Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 7 years
Number of subjects: 4074
Study: 24727329

Group type: EXPERIMENTAL
Intervention: erlotinib
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: erlotinib-sulindac
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 22841653

Group type: EXPERIMENTAL
Intervention: Intrauterine instillation of 95% tricholoroacetic acid
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical application of 95% tricholoroacetic acid after dilatation and curettage
Number of subjects: 70
Study: 20671333

Group type: EXPERIMENTAL
Intervention: Creative musical expression protocol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 17709061

Group type: EXPERIMENTAL
Intervention: Modified yoga-based exercise program (n=19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 37
Study: 15378664

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 240 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11548847

Group type: EXPERIMENTAL
Intervention: Post-APBSCT rhG-CSF administration (Group B and C)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No rhG-CSF administration (Group A)
Number of subjects: 38
Study: 9740345

Group type: EXPERIMENTAL
Intervention: Reviparin
Number of subjects: 612

Group type: COMPARATOR
Intervention: Unfractionated heparin/placebo
Number of subjects: 612
Study: 7799246

Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study: 3053750

Group type: EXPERIMENTAL
Intervention: Ad libitum home dietary conditions (E vs Y)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Very high (85%) carbohydrate diet (E)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low (30%) carbohydrate diet (Y)
Number of subjects: 18
Study: 28898922

Group type: EXPERIMENTAL
Intervention: Cold snare endoscopic mucosal resection (CS-EMR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hot snare endoscopic mucosal resection (HS-EMR)
Number of subjects: 155
Study: 30208765

Group type: EXPERIMENTAL
Intervention: Higher-income caregivers (88% aware of nutrition labels)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-income caregivers (51% aware of nutrition labels)
Number of subjects: 100
Study: 26678636

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban (60mg/30mg dose reduced)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban (30mg/15mg dose reduced)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 24248104

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouthwash 0.2%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Persica™ 10%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Matrica® (chamomile extracts) 10%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study: 21917021

Group type: EXPERIMENTAL
Intervention: 50 mg naftopidil daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: 8 mg silodosin daily
Number of subjects: 74
Study: 18709689

Group type: EXPERIMENTAL
Intervention: Oral dehydroepiandrosterone (DHEA) treatment (50 mg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: DHEA treatment in vitro
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saliva levels of resistin in pSS patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Circulating levels of resistin
Number of subjects: 37
Study: 16818971

Group type: EXPERIMENTAL
Intervention: Apprehension test
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Relocation test
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Anterior drawer test
Number of subjects: 46
Study: 12875613

Group type: EXPERIMENTAL
Intervention: galantamine 24 mg/day
Number of subjects: 182

Group type: COMPARATOR
Intervention: donepezil 10 mg/day
Number of subjects: 182
Study: 10575405

Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 157
Study: 8724619

Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 0
Study: 1653139

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg dispersible tablet)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Cafergot (2 mg ergotamine tartrate, 200 mg caffeine)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 580

Group type: COMPARATOR
Intervention: Cafergot
Number of subjects: 580
Study: 6214337

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30291797

Group type: EXPERIMENTAL
Intervention: Multimedia psychoeducation (MP) intervention
Number of subjects: 418

Group type: COMPARATOR
Intervention: Print education (PE) intervention
Number of subjects: 418
Study: 28438412

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) meal
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Theobromine added to LF meal
Number of subjects: 9
Study: 26232345

Group type: EXPERIMENTAL
Intervention: Short phone calls
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Short text messaging system (sms-text)
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: E-mails
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 1380
Study: 24014554

Group type: EXPERIMENTAL
Intervention: Intensive chelation therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ferritin levels above 1800 G/L
Number of subjects: 72

Group type: COMPARATOR
Intervention: High ferritin levels
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ferritin as a prognostic marker
Number of subjects: 72
Study: 21383657

Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil with microemulsified cyclosporine
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil with tacrolimus
Number of subjects: 830

Group type: COMPARATOR
Intervention: mycophenolate mofetil
Number of subjects: 830
Study: 18378748

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh repair
Number of subjects: 76

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 76
Study: 17020163

Group type: EXPERIMENTAL
Intervention: Divator Drogsan Pharmaceuticals (test formulation)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Lipitor (reference formulation)
Number of subjects: 52
Study: 15022654

Group type: EXPERIMENTAL
Intervention: Traditional Ayurvedic supplement
Number of subjects: 25
Study: 10859081

Group type: EXPERIMENTAL
Intervention: 60 mg of intravenous ketorolac at the onset of the procedure (Group B)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 60 mg of ketorolac mixed with local anesthetic (Group C)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (saline) injections (Group A)
Number of subjects: 123
Study: 9198713

Group type: EXPERIMENTAL
Intervention: Middlewave broadcast stations (exposed to EMF at 1 MHz)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Radioservice stations (exposed to EMF at about 150 MHz)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Radio line stations (exposed to EMF)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not exposed to EMF)
Number of subjects: 153
Study: 8459068

Group type: EXPERIMENTAL
Intervention: Intravenous Solu‐Medrol (1,000 mg for 3 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral prednisone (100 mg bolus for 3 days, tapering over 14 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous Solu‐Medrol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 41
Study: 3541604

Group type: EXPERIMENTAL
Intervention: Oral influenza vaccine (killed vaccine, 98 ug hemagglutinin of A/Bangkok)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31523905

Group type: EXPERIMENTAL
Intervention: Cognitive rehearsal intervention using a smartphone application
Number of subjects: 72
Study: 29583015

Group type: EXPERIMENTAL
Intervention: 1000 mg/day resveratrol
Number of subjects: 32

Group type: COMPARATOR
Intervention: 300 mg/day resveratrol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26537439

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg + MET + SU
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo + MET + SU
Number of subjects: 216
Study: 25179996

Group type: EXPERIMENTAL
Intervention: Active tDCS over the right DLPFC (n=5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Active tDCS over the left DLPFC (n=6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham tDCS (n=7)
Number of subjects: 18
Study: 23663561

Group type: EXPERIMENTAL
Intervention: 20-meter walk test (self-selected pace)
Number of subjects: 15
Study: 20199482

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1193
Study: 19064562

Group type: EXPERIMENTAL
Intervention: CYP19A1 polymorphisms (rs1004982, rs28566535, rs936306, rs4775936)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Haplotypes inferred using all polymorphisms
Number of subjects: 614
Study: 15898124

Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mild preeclampsia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy pregnancy
Number of subjects: 90
Study: 12788893

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion at a rate to raise local GH to approximately 40 ng/ml for 4 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10657837

Group type: EXPERIMENTAL
Intervention: Defective inactivation of leukotriene B4 (LTB(4))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Abnormal pattern of urinary excretion of LTB(4) and its metabolites
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Defective inactivation of LTB(4)
Number of subjects: 6
Study: 8634616

Group type: EXPERIMENTAL
Intervention: Health check conducted by nurse, with health education and follow up according to degree of risk
Number of subjects: 2205

Group type: COMPARATOR
Intervention: Control group (1916 patients who attended their initial health check in 1992‐3)
Number of subjects: 2205
Study: 1486816

Group type: EXPERIMENTAL
Intervention: Rooming-in hospital with breastfeeding guidance (RIBFG)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Rooming-in hospital without breastfeeding guidance (RI)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Nursery (NUR)
Number of subjects: 165
Study: 3899818

Group type: EXPERIMENTAL
Intervention: Neutral human insulin (0.3 U/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acid bovine soluble insulin (0.3 U/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moderate antibody levels
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acid bovine soluble insulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neutral human insulin
Number of subjects: 12
Study: 30084103

Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg)
Number of subjects: 20
Study: 28182466

Group type: EXPERIMENTAL
Intervention: Spiritual Strategies for Psychosocial Recovery (SSPR)
Number of subjects: 37
Study: 26650429

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 25438529

Group type: EXPERIMENTAL
Intervention: High-dose milk powder (55g daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-dose milk powder (33g daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control cycle (first and third menstrual cycles)
Number of subjects: 32
Study: 21711525

Group type: EXPERIMENTAL
Intervention: Action‐Observation Therapy (UP‐CAT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (computer games)
Number of subjects: 24